Simultaneous determination of bilirubin and its glucuronides in liver microsomes and recombinant UGT1A1 enzyme incubation systems by HPLC method and its application to bilirubin glucuronidation studies.

[1]  Song Gao,et al.  Mutual regioselective inhibition of human UGT1A1-mediated glucuronidation of four flavonoids. , 2013, Molecular pharmaceutics.

[2]  N. Lopes,et al.  In vitro metabolism study of the promising anticancer agent the lignan (-)-grandisin. , 2013, Journal of pharmaceutical and biomedical analysis.

[3]  K. Brouwer,et al.  A Perspective on Efflux Transport Proteins in the Liver , 2012, Clinical pharmacology and therapeutics.

[4]  J. Ghersi-Egea,et al.  Transport and Metabolism at Blood–Brain Interfaces and in Neural Cells: Relevance to Bilirubin-Induced Encephalopathy , 2012, Front. Pharmacol..

[5]  G. Giaccone,et al.  Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia , 2012, Clinical Cancer Research.

[6]  Shuxing Zhang,et al.  Evaluation of 3,3',4'-trihydroxyflavone and 3,6,4'-trihydroxyflavone (4'-O-glucuronidation) as the in vitro functional markers for hepatic UGT1A1. , 2011, Molecular pharmaceutics.

[7]  A. Sönnerborg,et al.  Bilirubin—A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy , 2011, The AAPS Journal.

[8]  D. Stevenson,et al.  Bilirubin production and the risk of bilirubin neurotoxicity. , 2011, Seminars in perinatology.

[9]  G. Gourley,et al.  Assessment of UGT polymorphisms and neonatal jaundice. , 2011, Seminars in perinatology.

[10]  B. Doumas,et al.  The status of bilirubin measurements in U.S. laboratories: why is accuracy elusive? , 2011, Seminars in perinatology.

[11]  T. Tracy,et al.  Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors , 2011, Drug Metabolism and Disposition.

[12]  T. Tracy,et al.  Bilirubin Glucuronidation Revisited: Proper Assay Conditions to Estimate Enzyme Kinetics with Recombinant UGT1A1 , 2010, Drug Metabolism and Disposition.

[13]  J. Quirke,et al.  The Animal Pigment Bilirubin Identified in Strelitzia reginae, the Bird of Paradise Flower , 2010 .

[14]  D. Chawla,et al.  Phenobarbitone for prevention and treatment of unconjugated hyperbilirubinemia in preterm neonates: A Systematic Review and Meta-analysis , 2010, Indian pediatrics.

[15]  M. Ratain,et al.  Comparison of the Drug-Drug Interactions Potential of Erlotinib and Gefitinib via Inhibition of UDP-Glucuronosyltransferases , 2010, Drug Metabolism and Disposition.

[16]  J. Ostrow,et al.  Bilirubin chemistry and metabolism; harmful and protective aspects. , 2009, Current pharmaceutical design.

[17]  Thomas K. H. Chang.  Activation of Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) by Herbal Medicines , 2009, The AAPS Journal.

[18]  Johan Fevery,et al.  Bilirubin in clinical practice: a review , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[19]  R. Wong,et al.  Highly sensitive method for quantitative determination of bilirubin in biological fluids and tissues. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  M. Mori,et al.  Transcriptional regulation of human UGT1A1 gene expression through distal and proximal promoter motifs: implication of defects in the UGT1A1 gene promoter , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[21]  J. Miners,et al.  Influence of mutations associated with Gilbert and Crigler–Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates , 2007, Pharmacogenetics and genomics.

[22]  M. Fakih,et al.  Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. , 2007, Clinical colorectal cancer.

[23]  H. Schwertner,et al.  The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. , 2007, Advances in clinical chemistry.

[24]  P. Mackenzie,et al.  INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE , 2006, Drug Metabolism and Disposition.

[25]  C. Strassburg,et al.  Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. , 2006, Journal of hepatology.

[26]  Donglu Zhang,et al.  IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION , 2005, Drug Metabolism and Disposition.

[27]  Amalio Telenti,et al.  Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. , 2005, The Journal of infectious diseases.

[28]  W. Spivak,et al.  separation , quantification and preparation of bilirubin and its conjugates from native bile , 2005 .

[29]  J. Ostrow,et al.  Molecular basis of bilirubin-induced neurotoxicity. , 2004, Trends in molecular medicine.

[30]  Masao Tanaka,et al.  Administration of Bacterial Lipopolysaccharide to Rats Induces Heme Oxygenase-1 and Formation of Antioxidant Bilirubin in the Intestinal Mucosa , 2000, Digestive Diseases and Sciences.

[31]  S. Shapiro,et al.  Bilirubin toxicity in the developing nervous system. , 2003, Pediatric neurology.

[32]  大谷 和広.  Administration of Bacterial Lipopolysaccharide to Rats Induces Heme Oxygenase-1 and Formation of Antioxidant Bilirubin in the Intestinal Mucosa , 2001 .

[33]  John,et al.  Hepatic Microsomal Bilirubin UDP-glucuronosyltransferase , 2001 .

[34]  S. Ghosh,et al.  Genetic lesions of bilirubin uridine‐diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler‐Najjar and Gilbert syndromes: Correlation of genotype to phenotype , 2000, Human mutation.

[35]  Y. Itoyama,et al.  Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer’s disease , 2000, Neurobiology of Aging.

[36]  M. Lew,et al.  Beyond Eyeballing: Fitting Models to Experimental Data , 2000, Critical reviews in biochemistry and molecular biology.

[37]  F. Kondo,et al.  Rapid and quantitative analysis of bilirubin in equines by high-performance liquid chromatography. , 1996, Microbios.

[38]  C. Berg.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphateglucuronosyltransferase , 1995 .

[39]  P. Bosma,et al.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. , 1994, The Journal of clinical investigation.

[40]  J. Ostrow,et al.  Structure and binding of unconjugated bilirubin: relevance for physiological and pathophysiological function. , 1994, Journal of lipid research.

[41]  B. Burchell,et al.  Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. , 1994, The Biochemical journal.

[42]  P. Bosma,et al.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. , 1994, The Journal of biological chemistry.

[43]  B. Ransil,et al.  Hepatic microsomal bilirubin UDP-glucuronosyltransferase. The kinetics of bilirubin mono- and diglucuronide synthesis. , 1992, Journal of Biological Chemistry.

[44]  H. Nakajima,et al.  Anti-bilirubin monoclonal antibody. III. Preparation and properties of monoclonal antibodies to unconjugated bilirubin-IX alpha. , 1991, Biochimica et biophysica acta.

[45]  T. Midtvedt,et al.  HPLC separation and quantification of bilirubin and its glucuronide conjugates in faeces and intestinal contents of germ-free rats , 1990 .

[46]  N. Blanckaert,et al.  Unconjugated and conjugated bilirubin pigments during perinatal development. II. Studies on serum of healthy newborns and of neonates with erythroblastosis fetalis. , 1990, Biology of the neonate.

[47]  T. Midtvedt,et al.  HPLC separation and quantification of bilirubin and its glucuronide conjugates in faeces and intestinal contents of germ-free rats. , 1990, Scandinavian journal of clinical and laboratory investigation.

[48]  W. Spivak,et al.  Application of a rapid and efficient h.p.l.c. method to measure bilirubin and its conjugates from native bile and in model bile systems. Potential use as a tool for kinetic reactions and as an aid in diagnosis of hepatobiliary disease. , 1986, The Biochemical journal.

[49]  T. Uesugi,et al.  Study of bilirubin metabolism by high-performance liquid chromatography: stability of bilirubin glucuronides. , 1985, Archives of biochemistry and biophysics.

[50]  N. Blanckaert,et al.  Liquid-chromatographic assay and identification of mono- and diester conjugates of bilirubin in normal serum. , 1983, Clinical chemistry.

[51]  E. Sasse,et al.  Standardization in bilirubin assays: evaluation of selected methods and stability of bilirubin solutions. , 1973, Clinical chemistry.

[52]  B. van Damme,et al.  Bilirubin conjugates in bile of man and rat in the normal state and in liver disease. , 1972, The Journal of clinical investigation.

[53]  O. Scremin,et al.  Transfer of bilirubin- 14 C between blood, cerebrospinal fluid, and brain tissue. , 1971, The American journal of physiology.

[54]  R. Schmid,et al.  Experimental bilirubin encephalopathy. The mode of entry of bilirubin-14C into the central nervous system. , 1966, The Journal of clinical investigation.